Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension

Study acronym: ATHESA
StatusWithdrawn
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Withdrawn before enrolling Sponsor's reason: Strategic change in development priorities. Show 4 more changesShow less
    • Enrollment target: estimated 292 to confirmed 0
    • Start date: Nov 30, 2026 to Jan 30, 2027
    • Interventions: Benicar HCT ® Tablets 40 mg/25 mg (Drug), N0877 (Drug) to Benicar HCT ® Tablets 40 mg/25 mg (Drug), N0877 (Drug)
    • Eligibility criteria expanded, about 16 words
  2. Site details revisedv4
  3. Enrollment target: 352 to 292
    • Study description shortened, about 12 words
    v3
  4. Study title shortened, about 16 wordsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on systolic blood pressure (SBP) in the sitting position in the medical office in patients with SAH after 8 weeks of treatment.
Trial Details
NCT Number NCT06608472
Lead Sponsor Eurofarma Laboratorios S.A.
Conditions
(from sponsor)		 Essential Arterial Hypertension
Related terms Hypertension
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov